ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, Dec. 3, 2024 /PRNewswire/ — Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug…Original Article
Saol Therapeutics Announces Submission of New Drug Application (NDA) to the U.S. FDA for SL1009
